These studies showed that targeting TGFβ signaling modulated the structure and function of the tumor vasculature, thereby increasing the drug delivery efficiency and antitumor efficacy of both conventional chemotherapeutic drugs and nanotherapeutics. The gene discussed is TGFB1; the disease is neoplasm.